461 related articles for article (PubMed ID: 28709704)
21. Endometrial Cancer Characteristics and Risk of Recurrence.
Borden LE; Locklear TM; Grider DJ; Osborne JL; Saks EJ; Valea FA; Iglesias DA
Am J Clin Pathol; 2022 Jan; 157(1):90-97. PubMed ID: 34463332
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers.
Kobayashi Y; Nakamura K; Nomura H; Banno K; Irie H; Adachi M; Iida M; Umene K; Nogami Y; Masuda K; Kisu I; Ueki A; Yamagami W; Kataoka F; Hirasawa A; Tominaga E; Susumu N; Aoki D
Int J Gynecol Cancer; 2015 Mar; 25(3):440-6. PubMed ID: 25695547
[TBL] [Abstract][Full Text] [Related]
24. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
25. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
26. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
27. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
28. Targeted gene sequencing of Lynch syndrome-related and sporadic endometrial carcinomas.
Libera L; Craparotta I; Sahnane N; Chiaravalli AM; Mannarino L; Cerutti R; Riva C; Marchini S; Furlan D
Hum Pathol; 2018 Nov; 81():235-244. PubMed ID: 30420047
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
30. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
Zighelboim I; Goodfellow PJ; Gao F; Gibb RK; Powell MA; Rader JS; Mutch DG
J Clin Oncol; 2007 May; 25(15):2042-8. PubMed ID: 17513808
[TBL] [Abstract][Full Text] [Related]
31. Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL; Liu YL; Devereaux KA; Paula ADC; Zhou QC; Ma W; Selenica P; Ceyhan-Birsoy O; Moukarzel LA; Hoang T; Gordhandas S; Rubinstein MM; Friedman CF; Aghajanian C; Abu-Rustum NR; Stadler ZK; Reis-Filho JS; Iasonos A; Zamarin D; Ellenson LH; Lakhman Y; Mandelker DL; Weigelt B
Clin Cancer Res; 2022 Oct; 28(19):4302-4311. PubMed ID: 35849120
[TBL] [Abstract][Full Text] [Related]
32.
Kaneko E; Sato N; Sugawara T; Noto A; Takahashi K; Makino K; Terada Y
J Gynecol Oncol; 2021 Nov; 32(6):e79. PubMed ID: 34431253
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
34. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
35. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
Shih KK; Garg K; Levine DA; Kauff ND; Abu-Rustum NR; Soslow RA; Barakat RR
Gynecol Oncol; 2011 Oct; 123(1):88-94. PubMed ID: 21742371
[TBL] [Abstract][Full Text] [Related]
37. A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome.
Walker R; Mahmood K; Joo JE; Clendenning M; Georgeson P; Como J; Joseland S; Preston SG; Antill Y; Austin R; Boussioutas A; Bowman M; Burke J; Campbell A; Daneshvar S; Edwards E; Gleeson M; Goodwin A; Harris MT; Henderson A; Higgins M; Hopper JL; Hutchinson RA; Ip E; Isbister J; Kasem K; Marfan H; Milnes D; Ng A; Nichols C; O'Connell S; Pachter N; Pope BJ; Poplawski N; Ragunathan A; Smyth C; Spigelman A; Storey K; Susman R; Taylor JA; Warwick L; Wilding M; Williams R; Win AK; Walsh MD; Macrae FA; Jenkins MA; Rosty C; Winship IM; Buchanan DD;
J Transl Med; 2023 Apr; 21(1):282. PubMed ID: 37101184
[TBL] [Abstract][Full Text] [Related]
38. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
Ta RM; Hecht JL; Lin DI
Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
[TBL] [Abstract][Full Text] [Related]
39. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
40. The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India.
Jain E; Prasad S; Dhar A; Kini L; Sharma S; Dewan A
Pathologica; 2021 Apr; 113(2):115-120. PubMed ID: 34042092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
